Metagenomi Inc (MGX) Stock Price, Quote & News

Company Profile

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medic...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 871 4880

Website: metagenomi.co

Address:

5959 Horton Street, 7th Floor, EmeryVille, United States

OfficialStocktwitsUser Jan. 5 at 10:54 AM

$MGX RSI: 44.93, MACD: -0.0640 Vol: 0.07, MA20: 1.71, MA50: 1.92 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Stmkr Jan. 4 at 7:48 PM

$MGX A quick summary for MGX https://substack.com/profile/160232761-biotech-pharma-investor/note/c-195232298?r=2nece1

0 · Reply

Bayesed Dec. 31 at 1:12 PM

$OTLK I remember when Sam Altman stood next to Trump in the White House for the Stargate project, and he mentioned MGX, a Gulf investment fund, and $MGX went flying pre-market. I expect something similar happened here, as few people knew about $CORT and immediately thought the rejection was for $OTLK Some investors should be away from the market

0 · Reply

SuperGreenToday Dec. 29 at 10:04 AM

$MGX

0 · Reply

VolSurface Dec. 25 at 3:22 PM

$MGX Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Margin stability needs to accompany any growth acceleration. Investors are likely to reward clarity more than ambition. Over time, credibility will hinge on repeatable performance.

0 · Reply

buffalosoldiertwo Dec. 19 at 4:06 PM

$MGX here we go again with the morons confusing $MGX with the Saudi hedge fund.

0 · Reply

PaulLaurent Dec. 16 at 6:39 AM

🚀📈 Top Gainers 📈🚀AH $KAVL $VIVK $MGX $QURE $ORGO

0 · Reply

topstockalerts Dec. 16 at 1:44 AM

After Hours Top Gainers PT2 $MGX $KAVL $QURE $ORGO $HCWB

0 · Reply

Dani_G_German Dec. 11 at 12:05 AM

$MGX any ideas as to why insiders in small quantities?

0 · Reply

stephllllll Dec. 8 at 4:57 PM

$MGX Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference. That's today.

1 · Reply

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Dec 1, 2025, 7:00 AM EST - 6 weeks ago

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Nov 17, 2025, 8:00 AM EST - 2 months ago

Metagenomi to Present at Jefferies Global Healthcare Conference in London

Nov 12, 2025, 12:09 PM EST - 2 months ago

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce

Nov 11, 2025, 4:02 PM EST - 2 months ago

Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates

Nov 11, 2025, 4:01 PM EST - 2 months ago

Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Oct 22, 2025, 10:02 AM EDT - 3 months ago

Metagenomi taps Amazon's custom chips to develop gene-editing tools

AMZN

Aug 12, 2025, 4:05 PM EDT - 5 months ago

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 5 months ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

KALV

May 14, 2025, 6:00 AM EDT - 8 months ago

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 13, 2025, 4:30 PM EDT - 8 months ago

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 7:00 AM EDT - 9 months ago

Metagenomi to Present at Upcoming Scientific Meetings

Mar 17, 2025, 4:05 PM EDT - 10 months ago

Metagenomi Reports Business Updates and Full Year 2024 Financial Results

Mar 13, 2025, 6:19 AM EDT - 10 months ago

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Feb 11, 2025, 8:55 AM EST - 1 year ago

Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference

Jan 16, 2025, 8:55 AM EST - 1 year ago

Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones

Jan 15, 2025, 8:55 AM EST - 1 year ago

Metagenomi Announces New Appointment to its Board of Directors

Jan 8, 2025, 4:05 PM EST - 1 year ago

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 6:30 PM EST - 1 year ago

Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”

Dec 9, 2024, 9:16 PM EST - 1 year ago

Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting

Nov 25, 2024, 11:30 AM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Nov 25, 2024, 9:56 AM EST - 1 year ago

FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Nov 24, 2024, 9:37 AM EST - 1 year ago

MGX Deadline: Rosen Law Firm Urges Metagenomi, Inc. (NASDAQ: MGX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Nov 23, 2024, 5:15 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Affected Stockholders Are Urged To Assist The Schall Law Firm

Nov 23, 2024, 1:00 PM EST - 1 year ago

MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit

Nov 22, 2024, 11:59 AM EST - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024

Nov 21, 2024, 12:00 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Contact The Schall Law Firm

Nov 20, 2024, 12:41 PM EST - 1 year ago

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights – MGX

Nov 20, 2024, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Investor Participation In A Fraud Case Against Metagenomi Inc

Nov 18, 2024, 1:30 PM EST - 1 year ago

The Schall Law Firm Invites Investors To Join A Fraud Case Against Metagenomi Inc

Nov 17, 2024, 3:00 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm

Nov 14, 2024, 9:18 PM EST - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Nov 13, 2024, 1:15 PM EST - 1 year ago

Metagenomi, Inc. Is Being Sued For Violating Securities Regulations And Shareholders With Losses Are Urged To Help The Schall Law Firm

OfficialStocktwitsUser Jan. 5 at 10:54 AM

0 · Reply

Stmkr Jan. 4 at 7:48 PM

$MGX A quick summary for MGX https://substack.com/profile/160232761-biotech-pharma-investor/note/c-195232298?r=2nece1

0 · Reply

Bayesed Dec. 31 at 1:12 PM

0 · Reply

SuperGreenToday Dec. 29 at 10:04 AM

$MGX

0 · Reply

VolSurface Dec. 25 at 3:22 PM

0 · Reply

buffalosoldiertwo Dec. 19 at 4:06 PM

$MGX here we go again with the morons confusing $MGX with the Saudi hedge fund.

0 · Reply

PaulLaurent Dec. 16 at 6:39 AM

🚀📈 Top Gainers 📈🚀AH $KAVL $VIVK $MGX $QURE $ORGO

0 · Reply

topstockalerts Dec. 16 at 1:44 AM

After Hours Top Gainers PT2 $MGX $KAVL $QURE $ORGO $HCWB

0 · Reply

Dani_G_German Dec. 11 at 12:05 AM

$MGX any ideas as to why insiders in small quantities?

0 · Reply

stephllllll Dec. 8 at 4:57 PM

$MGX Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference. That's today.

1 · Reply

I_am_retail_investor Dec. 4 at 2:02 AM

$MGX - volume up, price up !

0 · Reply

d_risk Nov. 12 at 4:31 PM

$MGX - Metagenomi Inc. Common Stock - 10Q - Updated Risk Factors MGX’s updated 10-Q risk factors stress heightened risks from third-party collaborations, expanded financial and operational uncertainties, new organizational change risks, increased challenges in IP protection and patent law, regulatory and clinical trial complexities, and potential setbacks from limited resources, leadership changes, and trademark vulnerabilities. #Biotechnology #ClinicalTrials #OperationalUncertainty #RegulatoryRisk #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/MGX/10-Q/2025-11-12

0 · Reply

JacksonHole Nov. 12 at 2:34 PM

$MGX nice open just kidding somebody didn’t like what they heard

1 · Reply

Koukla17 Nov. 12 at 12:48 AM

$MGX reducing the workforce by 25% 💪 streamlining MgX001 💪 cash runway until Q4 2027 ! Ionis has 2.5 billion in cash ! Letssssssss gooooo !

0 · Reply

Koukla17 Nov. 12 at 12:43 AM

$MGX $$$100 $TOCK .

0 · Reply

ZippedCookie Nov. 11 at 11:26 PM

$MGX a lot of analyst on the call today 👀

1 · Reply

DARKP00L Nov. 11 at 9:24 PM

$MGX 16:06 on Nov. 11 2025 Metagenomi Promotes Jian Irish To CEO, Appoints Willard Dere Board Chair #tradeideas

0 · Reply

DARKP00L Nov. 11 at 9:24 PM

$MGX 16:03 on Nov. 11 2025 Metagenomi Presents New Preclinical Data From MGX-001 Hemophilia A Program, Demonstrating Curative FVIII Activity In Non-Human Primates #tradeideas

0 · Reply

DonCorleone77 Nov. 11 at 9:12 PM

$MGX Metagenomi reduces workforce by 25%

0 · Reply

RAIK7 Nov. 11 at 9:04 PM

$MGX https://www.stocktitan.net/news/MGX/metagenomi-presents-new-preclinical-data-from-mgx-001-hemophilia-a-tmrumid6va8h.html

0 · Reply

AdiDasRom Nov. 7 at 3:12 PM

$MGX

0 · Reply

ThomasTrainTrader Nov. 4 at 8:16 PM

$RNAC it’s insane that $MGX is up 10% in the last year and this shit is down 60%. A company with essentially 0 viable assets has a +70% delta on a stock that has a best in class asset

0 · Reply

Market Cap	67.18M
Revenue (ttm)	52.30M
Net Income (ttm)	-78.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-149.25%
Debt to Equity Ratio	0.00

Volume	284,600
Avg Vol	382,608
Day's Range	N/A - N/A
Shares Out	37.53M
Stochastic %K	61%
Beta	0.50
Analysts	Strong Sell
Price Target	$9.33